ADAG: ערך הפעילות העסקית בספרים Adagene Inc

The financial stability of Adagene (ADAG) is supported by licensing payments from partners, which cover research costs, with the current figure standing at 0.09. Adagene (ADAG) has automated molecule synthesis using AI, although clinical trials still require physician oversight. This price chart confirms the platform's potential to create safe antibodies for combating tumors within the B2B segment.

Stable revenues from antibody licensing create a reliable financial foundation for Adagene, which directly increases the net asset value. The dynamics of the balance sheet capital structure demonstrate the difference between all assets and liabilities, allowing investors to assess the real value of equity without market distortions and recognize asset overheating in a timely manner.